LBPH Profile
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for neurological disorders. The company is engaged in advancing transformative medicines aimed at addressing significant unmet medical needs in the field of neurology. Longboard Pharmaceuticals is particularly focused on disorders that are challenging to treat with current therapies.
The company’s lead investigational product, LP352, is currently undergoing a Phase 1b/2a clinical trial to evaluate its efficacy in treating seizures associated with developmental and epileptic encephalopathies (DEEs). This product candidate represents a critical step in Longboard’s mission to provide new treatment options for patients with complex and severe neurological conditions. In addition to LP352, Longboard is advancing several other preclinical product candidates, including LP659 and LP143, which are designed to target a range of neurological diseases.
Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc., a name change that was completed in October 2020 to better reflect its focus on developing novel therapeutics for neurological conditions. Since its incorporation in 2020, the company has established its headquarters in La Jolla, California, positioning itself in a key hub for biopharmaceutical innovation and research.
The company is committed to advancing its pipeline of product candidates through rigorous clinical trials and preclinical research. Longboard Pharmaceuticals aims to deliver breakthroughs in the treatment of neurological disorders, leveraging its expertise in drug development to address the critical needs of patients and improve quality of life.
|
